Research search

Reset all

142 matching records Analyze trends Open JSON Open API Download SQLite

Keyword search Author

Substances Psilocybin 3833 Psilocin 553

Date range quick select Last month Last year Last 5 years All time Custom range

BibTeX RIS CSV JSON SQLite

Executed search Journal: bioRxiv 142 matching records are displayed.

Clear search

Latest Publications

Most recently published records currently stored in SQLite.

1-20

Last updated: Jul 2, 2026 23:06 UTC

Checking for newly published papers…

142 matching results

Rapid, biochemical tagging of cellular activity history in vivo

ABSTRACT Intracellular calcium (Ca 2+ ) is ubiquitous to cell signaling across all biology. While existing fluorescent sensors and reporters can detect activated cells with elevated Ca 2+ levels, these approaches require implants to deliver light to deep tissue, precluding their noninvasive use in freely-behaving animals. Here we engineered an enzyme-catalyz...

DOI 10.1101/2023.09.06.556431

bioRxiv 2023-09-07 Zhang R, Anguiano M, Aarrestad IK, Lin S, Chandra J, Vadde SS, Olson DE, Kim CK.

bioRxiv PREPRINT (not peer reviewed) psilocybin Mechanism of ActionAnimal Study Animal Study

Intravenous psilocybin administration attenuates mechanical hypersensitivity in a rat model of chronic pain

There is a renewed interest in the therapeutic potential of psychedelics, including psilocybin, in treating mental health disorders. However, there are no data on the efficacy of psilocybin in alleviating chronic pain. In this study, we investigated the effect of psilocybin on mechanical hypersensitivity and thermal hyperalgesia in a rat model of formalin-in...

DOI 10.1101/2023.08.26.554802

bioRxiv 2023-08-27 Kolbman N, Liu T, Guzzo P, Gilligan JP, Mashour GA, Vanini G, Pal D.

bioRxiv PREPRINT (not peer reviewed) psilocybin Chronic PainAnimal Study Animal Study

Novel psilocin prodrugs with altered pharmacological properties as candidate therapies for treatment-resistant anxiety disorders

The psychedelic compound psilocybin has shown therapeutic benefit in the treatment of numerous psychiatric diseases. A recent randomized clinical trial conducted at Johns Hopkins Bayview Medical Center demonstrated the efficacy of psilocybin-assisted therapy in the treatment of Major Depressive Disorder (MDD). Similarly, a phase IIb study evaluating psilocyb...

DOI 10.1101/2023.05.16.540994

bioRxiv 2023-05-17 Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, Sharma G, D D, Jensen G, Lee JB, Cai C, Gallant J, Bains JS, Tucker JE, Facchini PJ.

bioRxiv PREPRINT (not peer reviewed) psilocybinpsilocin DepressionAnxietyPharmacologyReceptor PharmacologyBiomarkersClinical TrialAnimal StudyIn Vitro StudyCancer PatientsTreatment-Resistant Depression Clinical Trial

Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience

Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybi...

DOI 10.1101/2023.05.11.540409

bioRxiv 2023-05-11 Singleton SP, Timmermann C, Luppi AI, Eckernäs E, Roseman L, Carhart-Harris RL, Kuceyeski A.

bioRxiv PREPRINT (not peer reviewed) psilocybin Brain ImagingPharmacologyReceptor PharmacologyConsciousness Other

High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin

Serotonergic psychedelics are emerging therapeutics for psychiatric disorders, yet their underlying mechanisms of action in the brain remain largely elusive. Zebrafish have evolutionarily conserved serotonergic circuits and subcortical targets such as the brainstem regions and the cerebellum, providing a promising model for studying the subcortical effects o...

DOI 10.1101/2023.04.13.536830

bioRxiv 2023-04-13 Braun D, Rosenberg A, Haruvi R, Malamud D, Barbara R, Kawashima T.

bioRxiv PREPRINT (not peer reviewed) psilocybin Mechanism of ActionReceptor Pharmacology Other

The Unique Neural Signature of Your Trip: Functional Connectome Fingerprints of Subjective Psilocybin Experience

The emerging neuroscientific frontier of brain fingerprinting has recently established that human functional connectomes (FCs) exhibit fingerprint-like idiosyncratic features, which map onto heterogeneously distributed behavioural traits. Here, we harness brain-fingerprinting tools to extract FC features that predict subjective drug experience induced by the...

DOI 10.1101/2023.03.20.532894

bioRxiv 2023-03-20 Tolle HM, Farah JC, Mallaroni P, Mason NL, Ramaekers JG, Amico E.

bioRxiv PREPRINT (not peer reviewed) psilocybin Brain ImagingDefault Mode NetworkAgingHealthy Volunteers Other

UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice

The effects of context on the subjective experience of serotonergic psychedelics have not been fully examined in human neuroimaging studies, partly due to limitations of the imaging environment. Here, we administered saline or psilocybin to mice in their home cage or an enriched environment, immunofluorescently-labeled brain-wide c-Fos, and imaged cleared ti...

DOI 10.1101/2023.02.19.528997

bioRxiv 2023-02-20 Rijsketic DR, Casey AB, Barbosa DA, Zhang X, Hietamies TM, Ramirez-Ovalle G, Pomrenze M, Halpern CH, Williams LM, Malenka RC, Heifets BD.

bioRxiv PREPRINT (not peer reviewed) psilocybin Brain ImagingAgingAnimal StudyDrug Interactions Animal Study

Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition

2,5-dimethoxy-4-bromophenethylamine (2C-B) is a hallucinogenic phenethylamine derived from mescaline. Observational and preclinical data have suggested it to be capable of producing both subjective and emotional effects on par with other classical psychedelics and entactogens. Whereas it is the most prevalently used novel serotonergic hallucinogen to date, i...

DOI 10.1101/2023.02.16.528808

bioRxiv 2023-02-15 Mallaroni P, Mason NL, Reckweg JT, Paci R, Ritscher S, Toennes SW, Theunissen EL, Kuypers KP, Ramaekers JG.

bioRxiv PREPRINT (not peer reviewed) psilocybin PharmacologyConsciousnessEmotional ProcessingObservational StudyAnimal Study Observational Study

Acute psilocybin enhances cognitive flexibility in rats

Psilocybin has been shown to improve symptoms of depression and anxiety when combined with psychotherapy or other clinician-guided interventions. To understand the neural basis for this pattern of clinical efficacy, experimental and conceptual approaches that are different than traditional laboratory models of anxiety and depression are needed. A potential n...

DOI 10.1101/2023.01.09.523291

bioRxiv 2023-01-08 Pacheco AT, Olson RJ, Garza G, Moghaddam B.

bioRxiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyPharmacologyReceptor PharmacologyHealthcare Workers Other

Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster

Psychoactive mushrooms in the genus Psilocybe have immense cultural value and have been used for centuries in Mesoamerica. Despite a recent surge in interest in these mushrooms due to emerging evidence that psilocybin, the main psychoactive compound, is a promising therapeutic for a variety of mental illnesses, their phylogeny and taxonomy remain substantial...

DOI 10.1101/2022.12.13.520147

bioRxiv 2022-12-14 Bradshaw AJ, Ramírez-Cruz V, Awan AR, Furci G, Guzmán-Dávalos L, Stamets P, Dentinger BT.

bioRxiv PREPRINT (not peer reviewed) psilocybin Genomics Other

Psychedelic compounds directly excite 5-HT2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT2A Gq -mediated activation mechanism

Summary Psilocin, the active compound in Psilocybe sp. mushrooms, is a serotonergic psychedelic that has recently gained renewed interest due to its potential as a therapeutic tool. Despite promising clinical findings, the underlying signaling mechanisms and brain region-specific effects of psilocin and other psychedelic drugs remain unclear. Psilocin, like ...

DOI 10.1101/2022.11.15.516655

bioRxiv 2022-11-14 Schmitz GP, Chiu Y, König GM, Kostenis E, Roth BL, Herman MA.

bioRxiv PREPRINT (not peer reviewed) psilocin NeuroplasticityMechanism of ActionReceptor PharmacologyAnimal StudyIn Vitro Study Animal Study

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice

ABSTRACT Serotonergic psychedelics are gaining increasing interest as potential therapeutics for a range of mental illnesses. Compounds with short-lived subjective effects may be clinically useful because dosing time would be reduced, which may improve patient access. One short-acting psychedelic is 5-MeO-DMT, which has been associated with improvement in de...

DOI 10.1101/2022.11.03.515044

bioRxiv 2022-11-02 Jefferson SJ, Gregg I, Dibbs M, Liao C, Wu H, Davoudian PA, Sprouse JS, Sherwood AM, Kaye AP, Pittenger C, Kwan AC.

bioRxiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyNeuroplasticityMechanism of ActionAnimal Study Animal Study

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: Translational implications

There is increasing interest in the therapeutic potential of psilocybin in psychiatric disorders. In common with other serotonergic psychedelics, psilocybin is thought to act via the 5-HT2A receptor (5-HT2AR). Serotonin is the endogenous ligand of 5-HTR. In rodents, the serotonin precursor, 5-hydroxytryptophan (5-HTP), and psilocybin, induce a characteristic...

DOI 10.1101/2022.07.22.501026

bioRxiv 2022-07-22 Shahar O, Botvinnik A, Esh-Zuntz N, Brownstien M, Wolf R, Wolf G, Lerer B, Lifschytz T.

bioRxiv PREPRINT (not peer reviewed) psilocybin Receptor PharmacologyAnimal Study Animal Study

Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder

Background Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble-burying, suggest that psilocybin may be effective in treating obsessive-compulsive disorder. Aims To explore 1) the role of 5-HT2A and 5-HT1A receptors in the effect of psilocybin on marble-burying; 2) the effect of staggered versus bolus ...

DOI 10.1101/2022.07.13.498401

bioRxiv 2022-07-13 Singh S, Botvinnik A, Shahar O, Wolf G, Yakobi C, Saban M, Salama A, Lotan A, Lerer B, Lifschytz T.

bioRxiv PREPRINT (not peer reviewed) psilocybin OCDReceptor PharmacologyAnimal Study Animal Study

Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape

To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain’s rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically-induced macroscale functional reorganisation, by relating the regional distribution of 19 neurotrans...

DOI 10.1101/2022.07.12.499688

bioRxiv 2022-07-12 Luppi AI, Hansen JY, Adapa R, Carhart-Harris RL, Roseman L, Timmermann C, Golkowski D, Golkowski D, Ranft A, Ilg R, Jordan D, Bonhomme V, Vanhaudenhuyse A, Demertzi A, Jaquet O, Bahri MA, Alnagger NL, Cardone P, Peattie ARD, Manktelow AE, de Araujo DB, Sensi SL, Owen AM, Naci L, Menon DK, Misic B, Stamatakis EA.

bioRxiv PREPRINT (not peer reviewed) psilocybin Receptor PharmacologyAging Other

Brain dynamics predictive of response to psilocybin for treatment-resistant depression

Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here we leveraged the differential outcome in responders and non-responders to psilocybin (10mg and 25mg, 7 days apart) therapy for depression - to gain new insights into regions and networks implicated in the restoration of healthy br...

DOI 10.1101/2022.06.30.497950

bioRxiv 2022-07-03 Vohryzek J, Cabral J, Lord L, Fernandes HM, Roseman L, Nutt DJ, Carhart-Harris RL, Deco G, Kringelbach ML.

bioRxiv PREPRINT (not peer reviewed) psilocybinpsilocin DepressionMechanism of ActionReceptor PharmacologyTreatment-Resistant Depression Other

Synapses, predictions, and prediction errors: a neocortical computational study of MDD using the temporal memory algorithm of HTM

Background Synapses and spines are central in major depressive disorder (MDD) pathophysiology, recently highlighted by ketamine’s and psilocybin’s rapid antidepressant effects. The Bayesian brain and interoception perspectives formalize MDD as being “stuck” in affective states constantly predicting negative energy balance. We examined how synaptic atrophy re...

DOI 10.1101/2022.06.29.498015

bioRxiv 2022-07-02 Sherif MA, Khalil MZ, Shukla R, Brown JC, Carpenter LL.

bioRxiv PREPRINT (not peer reviewed) psilocybin DepressionNeuroplasticityMechanism of Action Other

Electrical spiking of psilocybin fungi

Psilocybin fungi, aka “magic” mushrooms, are well known for inducing colourful and visionary states of mind. Such psychoactive properties and the ease of cultivating their basidiocarps within low-tech setups make psilocybin fungi promising pharmacological tools for mental health applications. Understanding of the intrinsic electrical patterns occurring durin...

DOI 10.1101/2022.07.02.498545

bioRxiv 2022-07-02 Gandia A, Adamatzky A.

bioRxiv PREPRINT (not peer reviewed) psilocybin General Other

Unique Effects of Sedatives, Dissociatives, Psychedelics, Stimulants, and Cannabinoids on Episodic Memory: A Review and Reanalysis of Acute Drug Effects on Recollection, Familiarity, and Metamemory

Despite distinct classes of psychoactive drugs producing putatively unique states of consciousness, there is surprising overlap in terms of their effects on episodic memory and cognition more generally. Episodic memory is supported by multiple subprocesses that have been mostly overlooked in psychopharmacology and could differentiate drug classes. Here, we r...

DOI 10.1101/2022.05.20.492842

bioRxiv 2022-05-23 Doss MK, Samaha J, Barrett FS, Griffiths RR, de Wit H, Gallo DA, Koen JD.

bioRxiv PREPRINT (not peer reviewed) psilocybin PharmacologyMechanism of ActionConsciousnessSystematic ReviewReview Article Systematic Review

Sex-Specific Effects of Psychedelic Drug Exposure on Central Amygdala Reactivity and Behavioral Responding

ABSTRACT Psilocybin, and its active metabolite psilocin, have been shown to elicit rapid and long-lasting symptom improvements in a variety of affective psychiatric illnesses. However, the region-specific alterations underlying these therapeutic effects remain relatively unknown. The central amygdala (CeA) is a primary output region within the extended amygd...

DOI 10.1101/2022.04.28.489882

bioRxiv 2022-04-28 Effinger D, Quadir S, Ramage M, Cone M, Herman M.

bioRxiv PREPRINT (not peer reviewed) psilocybinpsilocin Biomarkers Other

Email alerts Open a focused sheet to subscribe broadly or narrow notifications by keyword, author, journal, topic, substance, and cited DOI.

Analytics Open a focused analytics workspace for timeline ranges, publication trends, top journals, topics, and authors.

Source	Count	Share	Status
Europe PMC	2,553	64.2%	Active
PubMed	302	7.6%	Active
ClinicalTrials.gov	287	7.2%	Active
OpenAlex	283	7.1%	Active
PsyArXiv	216	5.4%	Active
Crossref	157	4%	Active
bioRxiv	142	3.6%	Active

Psilocybin Research Publication Tracker

Research search

Latest Publications